Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
Dari A, Boulton M, Neyens M, Le Gars M, Valenzuela B, Shukarev G, Cárdenas V, Ruiz-Guiñazú J, Sadoff J, Hoetelmans RMW, Ruixo JJP. Dari A, et al. Among authors: neyens m. Clin Pharmacol Ther. 2023 Feb;113(2):380-389. doi: 10.1002/cpt.2796. Epub 2022 Dec 9. Clin Pharmacol Ther. 2023. PMID: 36377532 Free PMC article.
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.
Dari A, Jacqmin P, Iwaki Y, Neyens M, Le Gars M, Sadoff J, Hardt K, Ruiz-Guiñazú J, Pérez-Ruixo JJ. Dari A, et al. Among authors: neyens m. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1485-1498. doi: 10.1002/psp4.13025. Epub 2023 Sep 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37715342 Free PMC article.
D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
Schmidt ME, de Boer P, Andrews R, Neyens M, Rossenu S, William Falteos D, Mannaert E. Schmidt ME, et al. Among authors: neyens m. Psychopharmacology (Berl). 2012 Dec;224(4):549-57. doi: 10.1007/s00213-012-2782-1. Epub 2012 Jul 7. Psychopharmacology (Berl). 2012. PMID: 22773165 Clinical Trial.
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H, Venkatasubramanian R, Neyens M, Gopal S, Russu A, Nandy P, Perez-Ruixo JJ, Ackaert O. T'jollyn H, et al. Among authors: neyens m. Eur J Drug Metab Pharmacokinet. 2024 Jul;49(4):491-506. doi: 10.1007/s13318-024-00899-z. Epub 2024 May 20. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38769284 Clinical Trial.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Goy A, Ganguly S, Salman M, Howes A, Mahler M, De Nicolao G, Poggesi I. Lavezzi SM, et al. Among authors: neyens m. Pharm Res. 2019 May 1;36(7):93. doi: 10.1007/s11095-019-2605-8. Pharm Res. 2019. PMID: 31044267 Clinical Trial.
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
T'jollyn H, Russu A, Venkatasubramanian R, Gopal S, Nandy P, Neyens M, Faelens R, Samtani MN, Ackaert O, Perez-Ruixo JJ. T'jollyn H, et al. Among authors: neyens m. Eur J Drug Metab Pharmacokinet. 2024 Jul;49(4):477-489. doi: 10.1007/s13318-024-00900-9. Epub 2024 May 15. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38750386 Clinical Trial.
12 results